Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials

Open access

Abstract

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the multinational trials to obtain the most precise estimates of the magnitude of treatment effect on measures of disease progression. All patients randomised to pirfenidone 2403 mg·day−1 or placebo in the CAPACITY or ASCEND studies were included in the analysis. Pooled analyses of outcomes at 1 year were based on the pre-specified end-points and analytic methods described in the ASCEND study protocol. A total of 1247 patients were included in the analysis. At 1 year, pirfenidone reduced the proportion of patients with a ≥10% decline in per cent predicted forced vital capacity or death by 43.8% (95% CI 29.3–55.4%) and increased the proportion of patients with no decline by 59.3% (95% CI 29.0–96.8%). A treatment benefit was also observed for progression-free survival, 6-min walk distance and dyspnoea. Gastrointestinal and skin-related adverse events were more common in the pirfenidone group, but rarely led to discontinuation. Analysis of data from three phase 3 trials demonstrated that treatment with pirfenidone for 1 year resulted in clinically meaningful reductions in disease progression in patients with IPF.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/13993003.00026-2015

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 FVC outcomes. a) Proportion of patients with forced vital capacity (FVC) % predicted decline ≥10% or death. Rank ANCOVA (pirfenidone 2403 mg·day−1 versus placebo). b) Cumulative distribution of change from baseline to month 12 in FVC % pred in the pooled population (n=1247). c) Mean change from baseline in FVC in the pooled population. Assessed at weeks 12, 24, 36 and 48 in CAPACITY [1] and weeks 13, 26, 39 and 52 in ASCEND [2].
FIGURE 1 FVC outcomes. a) Proportion of patients with forced vital capacity (FVC) % predicted decline ≥10% or death. Rank ANCOVA (pirfenidone 2403 mg·day−1 versus placebo). b) Cumulative distribution of change from baseline to month 12 in FVC % pred in the pooled population (n=1247). c) Mean change from baseline in FVC in the pooled population. Assessed at weeks 12, 24, 36 and 48 in CAPACITY [1] and weeks 13, 26, 39 and 52 in ASCEND [2].CC BY-NC · PubMed Central
FIGURE 2 Subgroup analysis of change in forced vital capacity (FVC) % predicted at 1 year in the pooled population. DLCO: diffusing capacity of the lung for carbon monoxide; 6MWD: 6-min walk distance; FEV1: forced expiratory volume in 1 s. p>0.05 for all tests for interaction between treatment and subgroup except time since diagnosis (nominal p=0.034; not corrected for multiple comparisons).
FIGURE 2 Subgroup analysis of change in forced vital capacity (FVC) % predicted at 1 year in the pooled population. DLCO: diffusing capacity of the lung for carbon monoxide; 6MWD: 6-min walk distance; FEV1: forced expiratory volume in 1 s. p>0.05 for all tests for interaction between treatment and subgroup except time since diagnosis (nominal p=0.034; not corrected for multiple comparisons).CC BY-NC · PubMed Central
FIGURE 3 Secondary outcomes. a) Proportion of patients with a decline in 6-min walk distance ≥50 m or death. Rank ANCOVA (pirfenidone 2403 mg·day−1 versus placebo). b) Progression-free survival at 1 year. Time to death or disease progression (confirmed ≥10% decline in forced vital capacity % predicted or ≥50 m decline in 6-min walk distance). c) Proportion of patients with an increase in UCSD SOBQ score ≥20 points or death. Rank ANCOVA (pirfenidone 2403 mg·day−1 versus placebo). HR: hazard ratio; UCSD SOBQ: University of California San Diego Shortness of Breath Questionnaire (scale 0–120; higher scores indicate worse dyspnoea). #: Cox proportional hazards model; ¶: log-rank test.
FIGURE 3 Secondary outcomes. a) Proportion of patients with a decline in 6-min walk distance ≥50 m or death. Rank ANCOVA (pirfenidone 2403 mg·day−1 versus placebo). b) Progression-free survival at 1 year. Time to death or disease progression (confirmed ≥10% decline in forced vital capacity % predicted or ≥50 m decline in 6-min walk distance). c) Proportion of patients with an increase in UCSD SOBQ score ≥20 points or death. Rank ANCOVA (pirfenidone 2403 mg·day−1 versus placebo). HR: hazard ratio; UCSD SOBQ: University of California San Diego Shortness of Breath Questionnaire (scale 0–120; higher scores indicate worse dyspnoea). #: Cox proportional hazards model; ¶: log-rank test.CC BY-NC · PubMed Central
FIGURE 4 Summary of clinical efficacy outcomes at 1 year in the pooled population (n=1247). FVC: forced vital capacity; 6MWD: 6-min walk distance; UCSD SOBQ: University of California San Diego Shortness of Breath Questionnaire; IPF: idiopathic pulmonary fibrosis.
FIGURE 4 Summary of clinical efficacy outcomes at 1 year in the pooled population (n=1247). FVC: forced vital capacity; 6MWD: 6-min walk distance; UCSD SOBQ: University of California San Diego Shortness of Breath Questionnaire; IPF: idiopathic pulmonary fibrosis.CC BY-NC · PubMed Central
FIGURE 5 Summary of clinical efficacy outcomes at 1 year across studies. FVC: forced vital capacity; 6MWD: 6-min walk distance; UCSD SOBQ: University of California San Diego Shortness of Breath Questionnaire; TE: treatment-emergent; IPF: idiopathic pulmonary fibrosis; STE: standardised treatment effect. p>0.05 for all tests for interaction between treatment and study. #: decline in FVC % predicted ≥10% or death; ¶: decline in 6MWD ≥50 m or death; +: increase in UCSD SOBQ score ≥20 points or death; §: estimated as the difference in the rank mean change from baseline between groups divided by the estimate of the common standard deviation from each study.
FIGURE 5 Summary of clinical efficacy outcomes at 1 year across studies. FVC: forced vital capacity; 6MWD: 6-min walk distance; UCSD SOBQ: University of California San Diego Shortness of Breath Questionnaire; TE: treatment-emergent; IPF: idiopathic pulmonary fibrosis; STE: standardised treatment effect. p>0.05 for all tests for interaction between treatment and study. #: decline in FVC % predicted ≥10% or death; ¶: decline in 6MWD ≥50 m or death; +: increase in UCSD SOBQ score ≥20 points or death; §: estimated as the difference in the rank mean change from baseline between groups divided by the estimate of the common standard deviation from each study.CC BY-NC · PubMed Central
FIGURE 6 a) Kaplan–Meier distribution of time to confirmed ≥10% decline in forced vital capacity (FVC) % predicted or death in the pooled population. b) Kaplan–Meier distribution of progression-free survival in the pooled population. Time to first occurrence of death or disease progression (confirmed >10% decline in FVC % pred or confirmed >50 m decrement in 6MWD). c) Kaplan–Meier distribution of time to confirmed ≥50 m decline in 6MWD or death in the pooled population. d) Kaplan–Meier distribution of time to worsening dyspnoea or death in the pooled population. Defined as a confirmed ≥20-point increase in UCSD SOBQ score or death. HR: hazard ratio; UCSD SOBQ: University of California San Diego Shortness of Breath Questionnaire (scale 0–120; higher scores indicate worse dyspnoea). #: Cox proportional hazards model; ¶: log-rank test. +: reported as the number of patients at risk on the last day of each 12-week study period in each study (excludes five patients from the pirfenidone group and six patients from the placebo group who had no post-randomisation follow-up assessment).
FIGURE 6 a) Kaplan–Meier distribution of time to confirmed ≥10% decline in forced vital capacity (FVC) % predicted or death in the pooled population. b) Kaplan–Meier distribution of progression-free survival in the pooled population. Time to first occurrence of death or disease progression (confirmed >10% decline in FVC % pred or confirmed >50 m decrement in 6MWD). c) Kaplan–Meier distribution of time to confirmed ≥50 m decline in 6MWD or death in the pooled population. d) Kaplan–Meier distribution of time to worsening dyspnoea or death in the pooled population. Defined as a confirmed ≥20-point increase in UCSD SOBQ score or death. HR: hazard ratio; UCSD SOBQ: University of California San Diego Shortness of Breath Questionnaire (scale 0–120; higher scores indicate worse dyspnoea). #: Cox proportional hazards model; ¶: log-rank test. +: reported as the number of patients at risk on the last day of each 12-week study period in each study (excludes five patients from the pirfenidone group and six patients from the placebo group who had no post-randomisation follow-up assessment).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 468

Metadata

Authors
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., Lancaster, L., Lederer, D. J., Leff, J. A., Nathan, S. D., Pereira, C. A., Swigris, J. J., Valeyre, D., & King, T. E.
Affiliations
  • Cedars-Sinai Medical Center (US)
  • University of Turin (IT)
  • Ruhrlandklinik (DE)
  • The Alfred Hospital (AU)
  • University of Miami (US)
  • Vanderbilt University Medical Center (US)
  • Columbia University Irving Medical Center (US)
  • Inova Fairfax Hospital (US)
  • Universidade Federal de São Paulo (BR)
  • National Jewish Health (US)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • University of California, San Francisco (US)
Corresponding author
Noble, Paul W.
Venue
European Respiratory Journal
Published
2015-12-02
Volume
47
Issue
1
Pages
243-253
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2208096782
Cited by
468
References
11
Citations by year
2026: 24 · 2025: 28 · 2024: 44 · 2023: 45 · 2022: 45 · 2021: 50 · 2020: 56 · 2019: 46 · 2018: 41 · 2017: 62 · 2016: 24 · 2015: 2
FWCI
33.96
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • European Respiratory Journal (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Monash University Research Portal (Monash University) (submittedVersion, cc-by-nc)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Funders
InterMune Inc.
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, CAPACITY trial, ASCEND trial
MeSH terms
Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Exercise Test, Female, Forced Expiratory Volume, Humans, International Cooperation, Male, Middle Aged, Pulmonary Diffusing Capacity, Pyridones, Vital Capacity, Randomized Controlled Trials as Topic, Treatment Outcome, Clinical Trials, Phase III as Topic, Disease Progression, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.